Cited by 225Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersAutoimmune Neurological Disorders and Treatments

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

Open access
Matthews, Lucy, Marasco, Rita, Jenkinson, Mark, Küker, Wilhelm, Luppe, Sebastian, Leite, Maria Isabel, Giorgio, Antonio, De Stefano, Nicola +4 more·2013·Neurology

Abstract

OBJECTIVE: Neuromyelitis optica and its spectrum disorder (NMOSD) can present similarly to relapsing-remitting multiple sclerosis (RRMS). Using a quantitative lesion mapping approach, this research aimed to identify differences in MRI brain lesion distribution between aquaporin-4 antibody-positive NMOSD and RRMS, and to test their diagnostic potential. METHODS: Clinical brain MRI sequences for 44 patients with aquaporin-4 antibody-positive NMOSD and 50 patients with RRMS were examined for the distribution and morphology of brain lesions. T2 lesion maps were created for each subject allowing the quantitative comparison of the 2 conditions with lesion probability and voxel-wise analysis. RESULTS: Sixty-three percent of patients with NMOSD had brain lesions and of these 27% were diagnostic of multiple sclerosis. Patients with RRMS were significantly more likely to have lesions adjacent to the body of the lateral ventricle than patients with NMOSD. Direct comparison of the probability distributions and the morphologic attributes of the lesions in each group identified criteria of "at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of a subcortical U-fiber lesion; or a Dawson's finger-type lesion," which could distinguish patients with multiple sclerosis from those with NMOSD with 92% sensitivity, 96% specificity, 98% positive predictive value, and 86% negative predictive value. CONCLUSION: Careful inspection of the distribution and morphology of MRI brain lesions can distinguish RRMS and NMOSD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182887957

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recently it has been recognised that some patients with NMOSD have brain lesions that may be difficult to distinguish from MS, with up to a quarter fulfilling Barkhof criteria.

    “Recently it has been recognised that some patients with NMOSD have brain lesions that may be difficult to distinguish from MS, with up to a quarter fulfilling Barkhof criteria.51”

    From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [51]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 20

  1. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spec- trum disorder and MS brain lesion distribution. Neurology 2013;80:1330-1337.
  2. Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011;68:1432-1439.
  3. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromy- elitis optica. Neurology 2007;68:1076-1077.
  4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
  5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
  6. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
  7. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 anti- bodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-919.
  8. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
  9. McDonald WI, Compston A, Edan G, et al. Recommen- ded diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
  10. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treat- ment in neuromyelitis optica: increase in relapses and aqua- porin 4 antibody titers. Arch Neurol 2010;67:1016-1017.
  11. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does inter- feron beta treatment exacerbate neuromyelitis optica spec- trum disorder? Mult Scler 2012;18:1480-1483.
  12. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-1032.
  13. Matthews LA, Baig F, Palace J, Turner MR. The borderland of neuromyelitis optica. Pract Neurol 2009;9:335-340.
  14. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
  15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
  16. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968.
  17. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
  18. Kincses ZT, Ropele S, Jenkinson M, et al. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. Mult Scler 2011;17:681-689.
  19. Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, et al. Brain magnetic resonance imaging findings in acute relapses of neu- romyelitis optica spectrum disorders. Mult Scler 2008;14: 248-251.
  20. Kim JE, Kim SM, Ahn SW, et al. Brain abnormalities in neuromyelitis optica. J Neurol Sci 2011;302:43-48.

Cited by

Sorted by citations

Authors
Matthews, L., Marasco, R., Jenkinson, M., Küker, W., Luppe, S., Leite, M. I., Giorgio, A., De Stefano, N., Robertson, N., Johansen-Berg, H., Evangelou, N., & Palace, J.
Affiliations
  • University of Siena (IT)
  • From the Nuffield Department of Clinical Neurosciences (L.M., R.M., M.J., W.K., M.I.L., H.J.-B., J.P.), University of Oxford; Institute of Psychological Medicine and Clinical Neurosciences (S.L., N.R.), University of Cardiff; Department of Neurological and Behavioural Sciences (A.G., N.D.S.), University of Siena; and Faculty of Medicine & Health Sciences (N.E.), University of Nottingham, UK.
Venue
Neurology
Published
2013-04-02
Volume
80
Issue
14
Pages
1330-1337
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2048103405
Cited by
225
References
2
Citations by year
2026: 7 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 27 · 2020: 20 · 2019: 20 · 2018: 15 · 2017: 17 · 2016: 24 · 2015: 16 · 2014: 19 · 2013: 12
FWCI
17.74
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Funders
  • Wellcome Trust (090955)
  • National Institute for Health and Care Research
  • Medical Research Council
  • NIHR Oxford Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
Keywords
neuromyelitis optica spectrum disorder, relapsing-remitting multiple sclerosis, aquaporin-4 antibodies, inferior temporal lobe, differential diagnosis, diagnostic criteria
MeSH terms
Adult, Aged, Autoantibodies, Brain, Brain Mapping, Cross-Sectional Studies, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Neuromyelitis Optica, Probability, Cohort Studies, Aquaporin 4, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review